Five things to know:
1. The investor group will be a “stalking horse” bidder to acquire Exactech’s assets and will support the company through restructuring.
2. Investors plan to provide about $85 million in additional financing to support the company’s operations.
3. Exactech will operate as normal during the restructuring process. The move will relieve Exactech from non-operating legacy liabilities and add new capital.
4. Darin Johnson, president and CEO of Exactech said, “Despite the strength of the underlying business, we face unsustainable liabilities associated with knee and hip litigation related to the packaging recalls we voluntarily initiated between 2021 and 2022. We take our commitment to patient well-being very seriously and have provided substantial out-of-pocket patient reimbursements and surgeon support for related expenses.”
5. Investors leading restructuring include private equity and alternative asset management firms who together represent more than $25 billion.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
